New Horizons - A White Paper: Navigating the Human Frontier of AI Adoption in Pharma

© Redbow Consulting Group 2026, All rights reserved New Horizons - A White Paper : Navigating the Human Frontier of AI Adoption in Pharma: Leadership, Culture, and Strategy in 2026 by Jonathan Dancer, MBA As we move deeper into the era of artificial intelligence (AI) , it has become evident that this revolution transcends pure technology. The technical capabilities of new models are clearly advancing at a breakneck pace; however, what remains most intricate and pivotal are those things that revolve around the human domain. This White Paper explores the adoption of AI in P harmaceutical s, specifically its commercial functions through a human rather than technology lens and the author has triangulated the findings with external cross - industry reports by Bain & Company , IBM’s Institute for Business Value, McKinsey, Deloitte, PwC, Capgemini, and the World Economic Forum. The work derives from a series of in - depth interviews with industry leaders conducted in April 2026 by the author , and b eyond detailing its qualitative findings, the report seeks to align these insights with prevailing themes in the general field of AI adoption . The outcome is a comprehensive reflection on how leadership vision, culture, governance, and workforce transformation are collectively shap ing the trajectory and value of AI within pharmaceutical organisations. It explores the themes of leadership vision, organisational culture, trust, governance, human factors, workforce transformation, and workflow embedding as critical vectors for capturing AI’s value and attempts to draw conclusions and recommendations . 1. From Leadership Sponsorship to Strategic CEO - Led Agentic AI Transformation Findings The successful adoption of AI in Pharma is inextricably linked to the vision and culture set by leadership. Insights from interviews underscore that companies progressing steadily with AI initiatives share a common denominator: robust sponsorship from top executives, particularly CEOs and CIOs. This leadership backing is more than symbolic; it acts as the driving catalytic force that shapes the very character of AI adoption efforts. Distinct leadership styles influence the approach to AI deployment — ranging from cautious, incremental adjustments to dynamic transformations that welcome experimentation and a “fail fast” attitude that tolerate s or even encourages failure. A respondent noted, “The CEO... pushed for us to really engage in leading [AI adoption ] , and it changed the culture a lot.” In the interviews , s uch commitment correlate d with companies fostering a culture that either embrace d structured governance with formalised training or promote d a trial - and - error ethos, empowering individuals to explore AI’s potential. Critically, leaders who frame AI as an augmentation — supporting rather than threatening existing roles — help to dissipate anxieties around job displacement. When this perspective is absent, scepticism and mistrust deepen. One interviewee observed, “The company about ‘AI is not going to take your job. [It’s about] t he person who’s going to take your job is somebody who knows how to use AI.’” This messaging is pivotal to fostering acceptance and encouraging proactive adoption rather than resistance. Interestingly, approaches vary significantly between organisations, perhaps shaped by cultural norms, leadership philosophies, or technological maturity. Some C Suites almost seemed to be falling over themselves to get on the “ AI travellator ” with a terrific sense of urgency or competition, where senior leaders are keen to position AI as a core competency or seeking a hallmark of being in the upper innovation quartile. “There was no clear roadmap, but a lot of buzz from senior people.”

© Redbow Consulting Group 2026, All rights reserved “There is a bit of FOMO created by stories of CEOs using multiple AI systems in every meeting.” O ne firm’s CIO leads a sophisticated AI initiative, including deploying an in - house [proprietary Gen AI] and a team of PhD experts, underscoring a hands - on, technologically grounded leadership style : “The CIO just lives and breathes this stuff.” Other organisations have baked accountability into senior roles: “[AI Implementation] is now a corporate key objective , driven by a senior executive accountable for it.” It is important to note that even with enthusiastic executive backing, workforce concerns remain a challenge. Disparate AI literacy levels and uncertainty about AI outputs contribute to wariness among employees, making transparent communication and targeted training even more crucial. Leaders who neglect these elements risk fostering disengagement or superficial compliance. The overarching lesson is clear: leadership is not merely about setting strategy but about cultivating an empathetic, empowering culture that accelerates genuine transformation. This includes careful pacing of AI initiatives to avoid burnout or reluctance, combined with cultivating forums where employee feedback on adoption barriers can be surfaced early and addressed constructively. External Reference The report’s finding that sustained executive sponsorship , especially from CEOs and CIOs , underpins effective AI adoption — resonates strongly with external themes advocating for CEO - led, cross - functional squads orchestrating enterprise - wide agentic AI transformations. Bain & Company notably emphasises that early adopters realise EBITDA uplifts of up to 25% by embedding AI agents into workflows, but crucially, this leap comes with a demand for rigorous leadership commitment to shift from fragmented pilots to aligned, scalable systems. “CEOs must champion moving beyond pilots to enterprise - wide agentic AI transformation...” (Bain & Co., 2025). This mirrors the shift from discrete AI experiments to cohesive roadmaps, reflecting the idea that leadership styles heavily influenc e cultural embrace and operational pacing. Importantly, the external literature introduces the “autonomy ladder” maturity model, encouraging pharma leaders to plan AI evolution along phased stages — from assistive tools to self - evolving agent meshes — thus underscoring the significance of the report’s recommendations about pacing and engagement. Recommendations: • Sustain prominent and steady executive sponsorship, with senior leaders actively championing AI as a means to augment performance and enhance decision - making processes. • Embed governance frameworks within leadership teams to carefully calibrate the tempo of AI rollout, ensuring innovation is pursued boldly but with due diligence to manage potential risks and employee engagement. • Develop and implement comprehensive, role - tailored AI literacy programmes that go beyond basic technical training, focusing on practical AI application aligned with specific job functions. • Foster open communication channels that encourage employee feedback, allowing organisations to promptly detect and address worries, misconceptions, or resistance . • Customize the AI adoption roadmap to reflect organisational size, culture, and maturity level, striking a balance between providing structured guidance and granting teams enough autonomy to innovate independently.

© Redbow Consulting Group 2026, All rights reserved 2. Culture and Workforce: The Crux of Hybrid Human - Agent Collaboration AI adoption is not predicated merely on technology availability but is overwhelmingly a people challenge. Disparities in AI literacy, widespread apprehension about job security, and fragmented or ineffective training undermine adoption momentum and behavio ural change. Beyond providing strategic sponsorship, the real challenge for pharmaceutical companies lies in embedding AI within their organisational culture and workforce fabric. AI’s integration is not simply technical; it reshapes how employees collaborate with intelligent systems, demanding a cultural shift and new workforce dynamics. As discussed in the previous section, L eadership’s tone - setting is vital in this cultural realignment. Where executives frame AI as a partner that amplifies human capability rather than a competitor, fear diminishes and curiosity grows. Yet, despite such assurances, adoption often encounters mi xed feelings among staff, with worries over job displacement and m istrust in AI outputs prevalent. This highlights a key cultural barrier: managing the human concerns at the heart of technological change. “If you are not gold level in AI training, you’re out of the job.” To overcome this, companies must engage in transparent communication combined with highly practical, role - specific training that goes beyond theoretical knowledge to focus on AI as a collaborative tool embedded in daily workflows. Organisations exhibit divergent adoption styles: from tightly controlled mandatory certification programmes to creating setting s that encourage individual - led experimentation , with tensions persisting between accelerating technological capability and human adaptation speed. S uccess seems to depend on striking a balance: clear leadership direction paired with employee empowerment and open dialogue. AI - driven efficiencies have begun transforming workforce structure s , notably replacing some traditional entry - level and roles that historically feed the talent pipeline. The transition towards hybrid human - agent roles also triggers organisational restructuring. Some organisations have proceeded at pace, with evidence that some senior staff are not necessarily fully engaged or even in agreement with some C suite decisions. For example, AI - driven efficiencies have led some companies to eliminate certain managerial positions, replacing human oversight with AI coaching capabilities. One respondent noted : “We have removed our first line sales managers in Europe and US like many other companies. AI coaching has taken their place.” [Researcher’s Note: This is not a quantitative sample, but his was the only example of widespread structural change already implemented]. Such shifts underscore the urgent need for fresh career pathways that blend AI proficiency with mentorship and experiential learning, ensuring workforce continuity , growth , and preserve critical talent pathways. Crucially, this cultural evolution hinges on empathetic change management strategies. Programmes anchored in clear communication, empowerment, and continuous support cultivate an environment where employees gradually adopt new behaviours and mindsets. Peer learning groups and mentorship networks are pivotal in facilitating this transition, enabling knowledge sharing that builds confidence in AI’s role. As one participant observed : “The speed at which you can learn and adapt is becoming more important than how good you are.” Trust in AI - generated insights is another essential cultural component. Without transparent validation processes and open discussion, employee scepticism tends to persist. Organisations that prioritise

© Redbow Consulting Group 2026, All rights reserved forums for dialogue and actively address concerns foster the trust needed for meaningful collaboration. In summary, leadership commitment paired with deliberate, human focused and culture - sensitive transformation forms the bedrock of successful AI integration in pharmaceutical environments. By positioning AI as a complementary partner, delivering tailored training, managing change transparently, and embracing open communication, co mpanies empower employees to confidently harness AI, thereby driving sustainable innovation. External Reference External perspectives also identify workforce transformation as the core challenge in realising AI’s potential. Observations of uneven AI literacy, job displacement anxieties, and the critical role of empathetic change management to normalise AI as augmentation are widely echoed . Supplementary insights from Deloitte and IBM specify a new workforce paradigm featuring M - shaped generalists orchestrating complex AI - human workflows and T - shaped domain experts managing specialist oversight and compliance — a hybrid talent ecosystem highly appropriate for pharma’s regulated environment. The external literature further details emergent roles - agentic process architects, autonomy auditors, and AI interaction coaches - that build on traditional change management framework s with systemic talent pipelines adapted to agentic AI’s sophistication. This emphasises the priority of embedding AI fluency into career frameworks and mentorship, w h ilst stressing continuous learning cultures to sustain resilience and innovation agility. Recommendations • Maintain continuous, visible leadership commitment — especially from CEOs and CIOs — to champion AI as an empowering tool and uphold a positive narrative around its integration. • Employ recognised change management frameworks, like Kotter’s 8 P rinciples, to lead empathetic, transparent transformations addressing employee concerns and cultivating a culture that embraces innovation. • Develop and implement tailored, role - specific AI literacy programmes that focus on practical collaboration rather than solely technical expertise, enabling employees to embed AI effectively in their workflows. • Integrate AI skills explicitly into talent management structures, including competency models, performance evaluation, graduate schemes, and career progression frameworks to normalise AI proficiency across the organisation. • Foster robust peer - learning networks, mentorship programmes, and practice communities that facilitate tacit knowledge sharing, build confidence in AI use, enhanc ing workforce resilience. • Create open and regular feedback mechanisms encouraging transparent dialogue about AI adoption challenges and successes, using employee input to adapt the overall approach and increase trust. • Communicate clearly and candidly about workforce implications related to AI adoption, outlining changes to career paths and new growth opportunities to sustain engagement and trust. • Promote transparency and destigmatisation initiatives that normalise conversations about AI, ensuring employees feel supported and informed.

© Redbow Consulting Group 2026, All rights reserved 3 . AI as a n Orchestrated, Interoperable System within Transformed Commercial Workflows Across the spectrum of pharmaceutical organisations spoken to , so far AI has been primarily employed as an augmentation tool embedded in existing commercial workflows rather than an instrument for radical operational redesign. Common applications include content generation, medical abstract synthesis, sales call planning, objection hand ling , coaching, and automating administrative tasks. “It’s the combination of human plus AI... not AI alone — that’s the key.” AI adoption flourishes where user - centric interfaces simplify the engagement - for example, natural language querying models that shield users from complex prompt engineering. Equally important is the “human in the loop” concept, where human oversight verifies AI outputs and manages risks such as hallucinations or inaccuracies. Despite promising progress, fragmented AI tool ecosystems persist. It seemed in some cases that individuals are simply augmenting their own workflow “ in a bubble” working in a more solitary albeit more efficient way , but without any overarching redesign of the overall workflow. This feels like a missed opportunity and certainly does not maximise the transformative potential of AI. Companies deploy proprietary AI variants, Microsoft Copilot, and multi - agent systems in silos, limiting scalability and end - to - end impact. For true progress and to fulfil strategic - level impact , consolidating these tools into integrated workflows is emerging as the next priority. “We’ve all been sent on a course with the [Prompt engineer ing programme] ... it set the tone in the business that we’re going to be using this.” The business value of AI manifests when it multiplies human capability in commercial functions by specialist tools , ensuring accuracy and alignment with strategic priorities. By contrast, disjointed pilots and optional tool use risk confining AI’s impact to incremental productivity gains. If it is true that individuals are becoming increasingly dependent on the AI tools at the elbow rather than coworkers, this raises the spectre o f social isolation . External Reference The Report explores the use of AI as an augmentation tool embedded in workflows to multiply human capability . This is affirm ed in the external documents’ elaboration on agentic AI mesh architectures. Bain and the World Economic Forum describe the shift toward modular, vendor - neutral agent ecosystems governed by communication protocols such as the Model Context Protocol (MCP) and Agent - to - Agent (A2A) standards. This architectural innovation addresses the challenge of avoiding fragmented AI tool ecosystems and advocates for integration into cohesive, interoperable platforms. The emergent agent mesh concept supports scalable autonomy w hilst maintaining compliance and governance rigor — a crucial balance for Pharma, which must navigat e complex regulatory constraints. “The agentic AI mesh paradigm supports composability, distributed intelligence, vendor neutrality, and governed autonomy...” (McKinsey, 2025). These frameworks provide the foundation to transform workflow augmentation into seamless autonomous collaboration between human expertise and agentic AI. O n the issue of social isolation , A recent article in the Harvard Business Review, HBR, May - June 2026 pp 67 - 75 concludes: “ Used thoughtfully, AI can give employees more time to connect and help them find ways to do so. But as AI becomes an ever - present companion in the workday, leaders must remain clear - eyed about what’s gained — and what may be lost — for the mental health of the

© Redbow Consulting Group 2026, All rights reserved organization. Left unchecked, AI can deepen work isolation, dull social motivation and skills, and quietly displace the small acts of help and empathy and the shared experiences through which coworkers build trust and belonging. It’s up to leaders to safeg uard their organizations against those dangers. ” Recommendations: • Prioritise integration of disparate AI functionalities into unified platforms to achieve scalable workflows. • Develop natural language front ends that lower technical barriers to AI adoption. • Embed AI tool usage as a mandated approach into standard workflows, linking competencies to performance metrics. • Invest in robust data infrastructures including tagging standards to supply AI engines with reliable, high - quality information. • Proactively manage AI’s social and organisational impacts to preserve team cohesion , social connection and trust

© Redbow Consulting Group 2026, All rights reserved 4 . Governing Agentic Autonomy: Balancing Trust, Transparency, and Innovation Quality data is the lifeblood of AI, and for pharmaceutical companies, this starts with standardisation across complex, often globally distributed datasets. Fragmented taxonomies, inconsistent data inputs, and lack of unified standards severely hinder AI e ffectiveness in marketing, customer engagement, and compliance functions. Governance structures, whilst essential for data security and regulatory compliance, often become cumbersome. Multiple committees, rigorous review processes, and stringent controls slow innovation and deployment, inadvertently prompting shadow AI usage on unsanctioned personal devices. Whilst technical functions and roles will continue to be fundamental to the creation of end embedding of the technology required to make AI work at scale in a commercial Pharma environment, it is the active participation and indeed leadership of operationa l managers with in all the key functions that make the difference. “Leaving the digital and business ops teams to execute was frustration... we had the tail wagging the dog.” Conversely, there is a phenomenon of “shiny object syndrome,” where attention is disproportionately allocated to highly visible but less fundamentally appropriate projects — animated videos, chatbots — that may not align well with healthcare professional needs. This dilutes resources and may reduce strategic focus. Legal and compliance teams play a crucial role in shaping AI use within pharma, often enforcing conservative risk postures to avoid regulatory infringement or reputational damage. This conservatism limits deployment of higher - risk applications, including m edical information bots or AI - powered sales simulations, due to concerns over hallucination risks and regulatory uncertainty. “ [Now] w e behave in a far more mature way... relying on trusted judgment rather than risk assessment by committee.” Metadata tagging and meta - tagging gaps further limit AI’s ability to discern content relevancy and customer interactions, fuelling user distrust. Without addressing these foundational issues, AI programmes risk producing misleading or suboptimal insights — p articularly detrimental within highly regulated pharmaceuticals environments. Governance mechanisms are evolving, such as AI project gateways and intellectual property safeguards, but inconsistent application across organisations underlines the need for coherent, cross - functional frameworks that balance caution and innovation. Contrasting styles were evident , from the ponderous and risk averse: “[Our] governance infrastructure is a dense and complicated process involving several committees, mainly due to concerns about data security and privacy” to the dynamic and nimble, turning proposals round in days: “There was a digital team and we kept the decisions in there – to make certain that technically we weren’t doing things that [were risky]” The critical challenge lies in balancing security and governance rigor with the agility necessary to embrace no - blame pilots rapidly, foster trust and prevent unsanctioned workarounds.

© Redbow Consulting Group 2026, All rights reserved External Reference The Report noted that stringent but sometimes cumbersome governance frameworks can lead to shadow AI adoption and slowed deployments: External sources extend this discussion by advocating progressive, risk - calibrated governance models that scale oversight proportional to agent autonomy and contextual complexity. The notion of layered control through human - in - the - loop (HITL) for high - risk tasks and human - on - the - loop (HOTL) for routine autonomy, combined with continuous auditing and ‘guardian’ supervisory agents, constitutes a new governance frontier. This balance maintains regulatory compliance and cybersecurity w hilst enabling innovation velocity — a tension explicitly acknowledged in the Report’s risk versus innovation theme. The imperative for cross - functional governance bodies involving legal, medical, IT and compliance stakeholders aligns with the comprehensive frame works emerging from WEF - Capgemini reports. Recommendations: • Establish comprehensive, enterprise - wide data governance frameworks standardising data formats and taxonomies to promote consistency and seamless interoperability. • Introduce dedicated AI stewardship roles tasked with expediting approvals and preserving governance agility, ensuring alignment with the rapid evolution of AI technologies. • Reinforce data tagging requirements through incentive schemes that motivate and reward compliance, fostering organisational - wide accountability. • Build secure, user - friendly internal AI platforms to curtail shadow IT and personal device usage, thereby strengthening data security and governance control. • Form cross - functional AI governance bodies comprising legal, medical, IT, compliance, and operational leadership to ensure robust oversight and cohesive decision - making. • Engage legal and compliance professionals early in the AI lifecycle to clarify acceptable use cases and establish monitoring mechanisms that mitigate regulatory risks. • Prioritise pilot projects that deliver tangible business benefits with manageable regulatory exposure, progressively cultivating organisational trust. • Recognise AI adoption as fundamentally a human - centred process, ensuring operational managers are deeply engaged and, ideally, lead initiatives even when technical experts drive the technical implementation.

© Redbow Consulting Group 2026, All rights reserved Conclusion: Synthesising Ambition, Pragmatism, and Human - Centricity for AI in Pharma The multifaceted interviews and synthesis presented illuminate a nuanced maturity continuum for AI adoption in pharmaceutical commercial functions. Leadership commitment and cultural framing emerge as the most potent levers in transcending both organisatio nal and technological barriers. The leader interviews strongly suggest that AI’s optimal value does not come from wholesale disruption, but from positioning it as an augmentation tool that enhances human expertise and decision - making. “It’s the combination of human plus AI... not AI alone — that’s the key.” This human - centric orientation necessitates ongoing, practical literacy programmes, empathetic change management, and trust - building measures. Without addressing employee fears and fostering cultural acceptance, AI risks being relegated to fragmented pilot s and voluntary usage patterns, limiting impact to modest efficiency gains rather than transformational improvements. S trong governance frameworks remain foundational yet vexing challenges , and b alancing innovation with risk management is an enduring tension. W hilst legal and compliance functions appropriately guard against regulatory and reputational risks, excessive conservatism or inconsistent governance can stifle scalable AI deployment. Cross - functional governance bodies that co - create clear guardrails and phase d rollouts are essential to safely accelerate adoption. The concomitant growth of shadow AI usage reflects systemic gaps in governance agility and digital enablement within organisations. I nconsistent data quality currently throttle s AI scalability , where f ragmented taxonomies and un - coded data persist . This work in progress leaves some organisations very early in the journey towards an AI - usable data set. Without this foundational work AI adoption cannot be truly transformative. Within the workforce, AI - driven efficiencies have already begun to reshape traditional roles, especially entry - level and front - line positions. A forward - looking talent strategy that incorporates AI skills alongside mentorship and experiential learning is critica l to sustaining organisational knowledge and creat es resilient career pathways. Change management programmes based on proven principles must be embedded to ensure both cultural normali s ation and behavioural adoption. Externally, the AI ecosystem is rapidly transforming market dynamics. Pharmaceutical companies must develop new competencies in generative AI optimisation and agility to navigate evolving customer behaviours and competitive landscapes. The ability to learn and adapt swiftly has become a more vital competitive differentiator than static excellence. In summary, the journey towards agentic AI maturity in pharma is neither purely technical nor linear. It calls for an integrated, people - first strategy combining visionary leadership, empathetic culture, sophisticated governance, workforce evolution, and r esponsive market engagement. Organisations embracing this holistic approach will unlock AI’s power not simply as an efficiency tool, but as a capabilit y multiplie r , driving sustained commercial impact and ultimately patient outcomes. Acknowledgements: The author’s sincere thanks go to the countless senior individuals who have contributed to this piece of work, giving their time and energy to unpack this complex subject. They and their companies have remained anonymous throughout the report to preserve confidential ity and they were given no incentive to participate other than to contri b u t e to the state of knowledge around the adoption of this game changing technology in an industry that is not just important to the healthcare system and the patients it serves, but to w h ich we are all so committed Disclaimer: This report was created with the assistance of AI tools. Content has been edited and verified for accuracy by Jonathan Dancer and reviewed by the human subject matter experts who contributed to this work . Whilst all efforts were made to ensure accuracy and the information contained herein does not constitute investment, professional, legal, or regulatory advice and should not be treated as a substitute for independent validation. The authors , contributors and publishers accept no liability for decisions made based on the report .

© Redbow Consulting Group 2026, All rights reserved Summary of Actionable Recommendations by Theme Executive Leadership and Governance • Ensure visible, thoughtful executive sponsorship with designated AI stewardship roles and strong leadership advocacy to promote positive AI narratives • Embed robust governance frameworks and cross - disciplinary AI oversight teams that balance innovation with risk management and accelerate progress through trial and error Communication and Organisational Culture • Foster transparent, ongoing communication , encourag ing open employee feedback , maintain ing trust and sustain ing team cohesion • Apply proven change management frameworks focused on empathetic, human - centred leadership to support cultural transformation AI Literacy and Talent Development • Deploy tailored, practical, role - specific AI literacy programmes that cater to varying employee needs and c ultivate peer learning and mentorship • Integrate AI skills development into broader talent development initiatives and career progression pathways Technology Integration and Data Management • Consolidate AI tools with intuitive natural language interfaces into unified, scalable platforms with secure, internal access to reduce reliance on shadow IT and support new workflows where this is beneficial • Strengthen data infrastructure through effective tagging, standardised governance, and consistent taxonomies External Ecosystem Engagement • Focus on a gile commercial models incorporating accelerated insight and response cycles. • M onitor AI - driven market trends and behaviours continuously to ensure learning and adaptation Social Impact and Ethical Considerations • Emphasise human - centred leadership in AI initiatives to balance technological capability with ethical and cultural sensitivity • Proactively manage AI’s social and organisational impacts to preserve team cohesion and trust Further information : For further information, please contact: Jonathan Dancer, Managing D irector, Redbow Consulting Group jonathan@redbowconsulting.com